Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Until today this year the stock’s price performance recorded an increase of 16.72%. However, over the last six months, the performance has been weaker by 5.01%. The price of PBYI increased 15.96% over the last 30 days. And in the last five days, it has surged by 5.64%.
The market performance of Puma Biotechnology Inc has been somewhat unstable.
52-week price history of PBYI Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Puma Biotechnology Inc’s current trading price is -13.80% away from its 52-week high, while its distance from the 52-week low is 60.00%. The stock’s price range over this timeframe has been between $2.22 and $4.13. The shares of the Healthcare sector company recorded a trading volume of approximately 0.68 million for the day, which was comparatively higher than the average daily volume of 0.37 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Puma Biotechnology Inc (PBYI) has experienced a quarterly rise of 0.56% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 176.71M and boasts a workforce of 172 employees.
How Moving Averages and Trading Volume Data Work Together
PBYI’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for PBYI stands at 0.64. Similarly, the long-term debt-to-equity ratio is also 0.11.
